logo

For the Inventor, By the Inventor

Tokyo, Japan

Eisai R&d Management Co., Ltd.


USPTO Granted Patents = 530



Trademarks = 42

Forward Citations = 3,210

Loading Chart...
Loading Chart...

833 inventors (with patents filed for the assignee):

goldMedal Francis Gerard Fang (51 out of 67 patents)

silverMedal Atsushi Endo (30 out of 30 patents)

bronzeMedal Charles E Chase (30 out of 30 patents)

4.  Keigo Tanaka (26 out of 31 patents)

5.  Lynn D Hawkins (24 out of 33 patents)

6.  Koichi Ito (21 out of 35 patents)

7.  Hyeong-wook Choi (20 out of 23 patents)

8.  Toshihiko Kaneko (19 out of 65 patents)

9.  Mamoru Takaishi (18 out of 18 patents)

10.  Nobuaki Sato (17 out of 24 patents)

11.  Yuichi Ono (17 out of 18 patents)

12.  Noritaka Kitazawa (17 out of 26 patents)

13.  Dae-Shik Kim (15 out of 15 patents)

14.  Yoshimasa Sakamoto (15 out of 16 patents)

15.  Toshio Imai (15 out of 25 patents)


Core Competencies:
Orexin-2 Receptor Antagonist
Double-Stranded Ribonucleic Acid
Diazabicyclo Compounds
Breast Cancer Therapeutics
Hepatocyte Growth Factor
Tumor-Treating Compositions
Splicing Modulator Antibody-Drug Conjugates
PD-1 Antagonists
EZH2 Inhibitors
Macrocyclic Compounds
Cancer Combination Therapies
Anti-Tau Antibodies

530 patents:

1. 12514926 - SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE (2026-01-06),
2. 12508313 - Quinoline derivative-containing pharmaceutical composition (2025-12-30),
3. 12504431 - Biomarkers for a therapy comprising a sorafenib compound (2025-12-23),
4. 12479819 - Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities (2025-11-25),
5. 12447173 - Pharmaceutical composition containing double-stranded ribonucleic acid inhibiting expression of complement C5 (2025-10-21),
6. 12421248 - Macrocyclic compound and uses thereof (2025-09-23),
7. 12421246 - Method for synthesis of diazabicyclo[6.2.0]decane related compounds (2025-09-23),
8. 12414945 - Therapeutic agent for breast cancer (2025-09-16),
9. 12384824 - Method for producing an active hepatocyte growth factor (HGF) (2025-08-12),
10. 12364690 - Therapeutic agent for bile duct cancer (2025-07-22),
11. 12303505 - Tumor-treating pharmaceutical composition (2025-05-20),
12. 12303499 - Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds (2025-05-20),
13. 12253526 - Fluorescent dye and use thereof (2025-03-18),
14. 12251394 - Methods for the treatment of bladder cancer (2025-03-18),
15. 12251386 - Salt form of a human histone methyltransferase EZH2 inhibitor (2025-03-18),
Eisai R&D Management Co., Ltd. is a leading global pharmaceutical company specializing in research and development. With a focus on innovation, they strive to create new therapeutic solutions that address unmet medical needs and improve the lives of patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

...
530 Patents

#156 in Tokyo

#358 in Japan

#1,791 in the World

...
Tokyo, Japan

Eisai R&d Management Co., Ltd.

Forward Citations = 3,210

833 inventors:

goldMedal Francis Gerard Fang (51 out of 67 patents)

silverMedal Atsushi Endo (30 out of 30 patents)

bronzeMedal Charles E Chase (30 out of 30 patents)

4.  Keigo Tanaka (26 out of 31 patents)

5.  Lynn D Hawkins (24 out of 33 patents)

Please report any incorrect information to support@idiyas.com
Loading…